Brian P Burns

US Patent:

8461851, Jun 11, 2013

Filed:

Apr 9, 2010

Appl. No.:

12/757859

Inventors:

Magdy F. Iskander - Honolulu HI, US
Hyoungsun Youn - Honolulu HI, US
Charles Amazeen - Arlington VA, US
Brian Burns - Alexandria VA, US

Assignee:

University of Hawaii - Honolulu HI

International Classification:

G01R 27/04

US Classification:

324637, 324642, 324639

Abstract:

A slotted TEM transmission line and an in-situ TEM transmission line are utilized to determine both complex permittivity and permeability of soil. The permittivity and permeability information may be used by underground sensing techniques such as GPR and EMI to enhance information from these techniques. The in-situ probe provides that both complex permittivity and permeability can be measured simultaneously over a broad frequency range without disturbing the soil conditions.

US Patent:

20020064852, May 30, 2002

Filed:

May 14, 2001

Appl. No.:

09/855154

Inventors:

Caretha Creasy - Erdenheim PA, US
Brian Burns - King of Prussia PA, US

Assignee:

SmithKline Beecham Corporation/SmithKline Beecham plc.

International Classification:

C12N009/12
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/194000, 435/069100, 435/325000, 536/023200

Abstract:

Mus Musculus mDYRK2 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize Mus Musculus mDYRK2. Such compounds are expected to be useful in treatment of human diseases, including, but not limited to: bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; infertility; cancers; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome .

US Patent:

20030077679, Apr 24, 2003

Filed:

Sep 24, 2002

Appl. No.:

10/253349

Inventors:

Roland Annan - King of Prussia PA, US
Brian Burns - King of Prussia PA, US
Caretha Creasy - King of Prussia PA, US
Kathleen Herold - King of Prussia PA, US

International Classification:

G01N033/53
G01N033/537
G01N033/543
C12Q001/42

US Classification:

435/007920, 435/021000

Abstract:

Methods of finding agonists and antagonists to DYRK3 or DYRK2 are provided.